Histologic Results

DUPIXENT DEMONSTRATED GREATER HISTOLOGIC IMPROVEMENTS IN CHILDREN AS YOUNG AS 1 YEAR^1,2

Histologic improvements were observed at Week 16 and Week 52^1,2

Histologic Remission^1,2
(≤6 EOS/HPF peak esophageal
intraepithelial EOS count)

Histologic Response^1,2
(<15 EOS/HPF peak esophageal
intraepithelial EOS count)

Percentage of patients

Week 16
EoE KIDS-Part A
Primary Endpoint Week 52
EoE KIDS-Part B
Secondary Endpooint

P<0.0001

66 %

DUPIXENT
(n=32)

3 %

Placebo
(n=29)

53 %

DUPIXENT
(n=32)

53 %

Switch to
DUPIXENT
(n=15)

Week 16
EoE KIDS-Part A
Secondary Endpoint Week 52
EoE KIDS-Part B
Secondary Endpoint

P<0.0001

81 %

DUPIXENT
(n=32)

3 %

Placebo
(n=29)

78 %

DUPIXENT
(n=32)

67 %

Switch to
DUPIXENT
(n=15)

Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.²

Peak Esophageal Intraepithelial Eosinophil Count

Used to confirm diagnosis and determine treatment response. Histologic data are reported as the percentage of patients achieving the defined EOS threshold.⁴

EOS, eosinophil: EOS/HPF, eosinophils per high-power field.

DUPIXENT DEMONSTRATED GREATER HISTOLOGIC IMPROVEMENTS IN CHILDREN AS YOUNG AS 1 YEAR1,2

Peak Esophageal Intraepithelial Eosinophil Count

DUPIXENT DEMONSTRATED GREATER HISTOLOGIC IMPROVEMENTS IN CHILDREN AS YOUNG AS 1 YEAR^1,2